Maze Therapeutics (MAZE) Competitors $26.35 +0.17 (+0.65%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MAZE vs. ACAD, ADMA, AAPG, MTSR, LNTH, MIRM, PTGX, ZLAB, AKRO, and MLTXShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), Metsera (MTSR), Lantheus (LNTH), Mirum Pharmaceuticals (MIRM), Protagonist Therapeutics (PTGX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Its Competitors ACADIA Pharmaceuticals ADMA Biologics Ascentage Pharma Group International Metsera Lantheus Mirum Pharmaceuticals Protagonist Therapeutics Zai Lab Akero Therapeutics MoonLake Immunotherapeutics ACADIA Pharmaceuticals (NASDAQ:ACAD) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Do analysts rate ACAD or MAZE? ACADIA Pharmaceuticals currently has a consensus price target of $29.53, indicating a potential upside of 39.22%. Maze Therapeutics has a consensus price target of $32.67, indicating a potential upside of 23.97%. Given ACADIA Pharmaceuticals' higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the media refer more to ACAD or MAZE? In the previous week, ACADIA Pharmaceuticals had 14 more articles in the media than Maze Therapeutics. MarketBeat recorded 25 mentions for ACADIA Pharmaceuticals and 11 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 0.43 beat ACADIA Pharmaceuticals' score of 0.14 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Neutral Maze Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in ACAD or MAZE? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ACAD or MAZE more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to Maze Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Maze Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals21.80% 14.69% 9.41% Maze Therapeutics N/A N/A N/A Which has stronger earnings and valuation, ACAD or MAZE? ACADIA Pharmaceuticals has higher revenue and earnings than Maze Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$957.80M3.74$226.45M$1.3315.95Maze Therapeutics$167.50M6.90$52.23MN/AN/A SummaryACADIA Pharmaceuticals beats Maze Therapeutics on 10 of the 14 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E RatioN/A20.6375.7726.11Price / Sales6.90442.69544.74124.93Price / Cash171.0144.6737.5461.24Price / Book-3.719.6212.876.30Net Income$52.23M-$52.73M$3.29B$271.03M7 Day Performance12.22%0.64%-0.26%-0.15%1 Month Performance97.97%6.31%3.84%6.41%1 Year PerformanceN/A18.97%68.35%28.81% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze Therapeutics3.3406 of 5 stars$26.35+0.6%$32.67+24.0%N/A$1.15B$167.50M0.00121ACADACADIA Pharmaceuticals4.3156 of 5 stars$23.61-2.4%$29.65+25.6%+34.2%$4.08B$957.80M17.75510Trending NewsAnalyst ForecastOptions VolumeADMAADMA Biologics3.2447 of 5 stars$16.11flat$27.67+71.7%-18.8%$3.84B$426.45M18.73530Positive NewsAAPGAscentage Pharma Group InternationalN/A$40.46+1.4%N/AN/A$3.76B$390.60M0.00600Positive NewsGap UpMTSRMetseraN/A$35.67-4.2%$63.50+78.0%N/A$3.75BN/A0.0081Analyst DowngradeLNTHLantheus4.5136 of 5 stars$52.94-3.7%$91.60+73.0%-52.4%$3.74B$1.53B14.08700Trending NewsMIRMMirum Pharmaceuticals3.2919 of 5 stars$74.31-2.2%$74.44+0.2%+90.5%$3.73B$429.16M-61.41140Analyst ForecastPTGXProtagonist Therapeutics1.6854 of 5 stars$58.86-1.4%$67.73+15.1%+41.6%$3.71B$209.18M84.09120Insider TradeZLABZai Lab3.0662 of 5 stars$32.80+1.0%$56.35+71.8%+50.6%$3.63B$398.99M-16.081,869AKROAkero Therapeutics3.9537 of 5 stars$43.46-3.3%$81.14+86.7%+69.2%$3.59BN/A-21.7330Gap UpMLTXMoonLake Immunotherapeutics2.389 of 5 stars$52.62-3.1%$74.43+41.4%-0.6%$3.49BN/A-18.932Positive News Related Companies and Tools Related Companies ACADIA Pharmaceuticals Competitors ADMA Biologics Competitors Ascentage Pharma Group International Competitors Metsera Competitors Lantheus Competitors Mirum Pharmaceuticals Competitors Protagonist Therapeutics Competitors Zai Lab Competitors Akero Therapeutics Competitors MoonLake Immunotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MAZE Stock Alerts